论文部分内容阅读
目的:评价某“三甲”医院口服抗消化性溃疡药的应用情况及趋势。方法:对某“三甲”医院2009-2011年口服抗消化性溃疡药的销售金额、用药频度(DDDs)及日均费用(DDC)等进行回顾性分析。结果:从各类药物的销售金额构成比来看,质子泵抑制剂所占比例最大,每年均在65%以上;其次是胃黏膜保护药,每年均在18%以上。从单品种药物来看,各年度销售金额排在前3位的均是雷贝拉唑、兰索拉唑、泮托拉唑。从DDDs排序来看,各年度居前列的均为雷贝拉唑、奥美拉唑和雷尼替丁。结论:该院口服抗消化性溃疡药的应用符合消化性溃疡的药物治疗原则,也代表了现代临床用药的趋势和方向,其中质子泵抑制剂占主导地位。
Objective: To evaluate the application and trend of oral anti-peptic ulcer drugs in a “top three ” hospital. Methods: Retrospective analysis was conducted on the sales amount, frequency of medication (DDDs) and daily average cost (DDC) of oral anti-peptic ulcer drugs in a hospital from 2009 to 2011 in a “Three A” hospital. Results: From the composition ratio of sales of all kinds of drugs, proton pump inhibitors accounted for the largest proportion, more than 65% each year; followed by gastric mucosal protective drugs, each year at 18% or more. From a single species of drug point of view, the annual sales amount of the top three are rabeprazole, lansoprazole, pantoprazole. From the DDDs sort of view, the highest in each year are rabeprazole, omeprazole and ranitidine. Conclusion: The hospital oral administration of anti-peptic ulcer drugs in line with the principle of peptic ulcer medication, but also represents the trend of modern clinical medication and direction, of which proton pump inhibitors dominate.